The pharmacogenetics of antidepressant treatments for depressive disorders

Min-Soo Lee

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

Original languageEnglish
Pages (from-to)170-178
Number of pages9
JournalDrug Development Research
Volume65
Issue number3
DOIs
Publication statusPublished - 2005 Jul 1

Fingerprint

Pharmacogenetics
Depressive Disorder
Antidepressive Agents
Receptor, Serotonin, 5-HT2A
Norepinephrine Plasma Membrane Transport Proteins
Tryptophan Hydroxylase
Serotonin Plasma Membrane Transport Proteins
Protein Subunits
Genetic Polymorphisms
Therapeutics
Polymorphism
Genetic Markers
GTP-Binding Proteins
Gold
Pharmacology

Keywords

  • Depression
  • Norepinephrine transporter
  • Pharmacogenetics
  • Serotonin transporter
  • Tryptophan hydroxylase

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

The pharmacogenetics of antidepressant treatments for depressive disorders. / Lee, Min-Soo.

In: Drug Development Research, Vol. 65, No. 3, 01.07.2005, p. 170-178.

Research output: Contribution to journalReview article

@article{7e1757c9547042bca5d6aa6072f4da8b,
title = "The pharmacogenetics of antidepressant treatments for depressive disorders",
abstract = "Pharmacological treatments for depressive disorder vary between individuals, with 30-40{\%} of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.",
keywords = "Depression, Norepinephrine transporter, Pharmacogenetics, Serotonin transporter, Tryptophan hydroxylase",
author = "Min-Soo Lee",
year = "2005",
month = "7",
day = "1",
doi = "10.1002/ddr.20020",
language = "English",
volume = "65",
pages = "170--178",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - The pharmacogenetics of antidepressant treatments for depressive disorders

AU - Lee, Min-Soo

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

AB - Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

KW - Depression

KW - Norepinephrine transporter

KW - Pharmacogenetics

KW - Serotonin transporter

KW - Tryptophan hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=28444436223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444436223&partnerID=8YFLogxK

U2 - 10.1002/ddr.20020

DO - 10.1002/ddr.20020

M3 - Review article

VL - 65

SP - 170

EP - 178

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 3

ER -